Accessibility StatementSkip Navigation NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). Shareholders who purchased shares of NUTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. DEADLINE: October 21, 2025 Shareholders should not delay in registering for this class action. Register ...

[Filing Information](index=1&type=section&id=Filing%20Information) This section provides essential administrative details regarding the Form 8-K filing, including registrant identity and securities information [General Information](index=1&type=section&id=General%20Information) This section provides the foundational details of the Form 8-K filing, including the registrant's identity, jurisdiction, and the date of the report - Registrant: **NUTEX HEALTH INC.**[2](index=2&type=chunk) - Date of Report (Date of earliest event reported): **October 20, 2025**[2](index=2&type=chunk) - State or Other Jurisdiction of Incorporation: **Delaware**[2](index=2&type=chunk) [Securities Information](index=1&type=section&id=Securities%20Information) This part details the company's registered securities and its status regarding emerging growth company provisions Securities Registered Pursuant to Section 12(b) of the Act | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value | NUTX | The NASDAQ Stock Market LLC | - The registrant is **not an emerging growth company**[4](index=4&type=chunk) [Current Report Items](index=2&type=section&id=Current%20Report%20Items) This section details significant events including preliminary financial results, a Nasdaq delisting notice, and a list of filed exhibits [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Nutex Health Inc. issued a press release on October 20, 2025, providing anticipated preliminary financial metrics for the quarter ended September 30, 2025. This information is furnished, not filed, under SEC regulations - On **October 20, 2025**, Nutex Health Inc. issued a press release (Exhibit 99.1) containing anticipated preliminary financial metrics for the period ended **September 30, 2025**[5](index=5&type=chunk) - The information furnished in this Item 2.02 and Exhibit 99.1 is **not deemed 'filed'** for purposes of Section 18 of the Securities Exchange Act of 1934[6](index=6&type=chunk) [Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](index=2&type=section&id=Item%203.01%20Notice%20of%20Delisting%20or%20Failure%20to%20Satisfy%20a%20Continued%20Listing%20Rule%20or%20Standard%3B%20Transfer%20of%20Listing) The Company received a Nasdaq notice of non-compliance due to the late filing of its June 30, 2025 Form 10-Q. Nutex Health submitted a compliance plan and was granted an extension until December 12, 2025, to rectify the filing deficiency - On **August 20, 2025**, the Company received a notice from Nasdaq for non-compliance with Listing Rule 5250(c)(1) due to the failure to timely file its Quarterly Report on Form 10-Q for the period ended **June 30, 2025**[7](index=7&type=chunk) - The Company submitted a plan to Nasdaq on **October 15, 2025**, to regain compliance and requested an extension until **December 12, 2025**[8](index=8&type=chunk) - Nasdaq granted the extension request on **October 16, 2025**; failure to file the Form 10-Q by **December 12, 2025**, will result in a delisting notice[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits included with the Form 8-K filing, specifically identifying the press release mentioned in Item 2.02 Exhibits | Exhibit No. | Description of Exhibit | | :---------- | :--------------------------- | | 99.1 | Press Release dated October 20, 2025 | [Signature](index=3&type=section&id=Signature) This section confirms the official signing and submission of the report by the company's Chief Financial Officer [Report Signature](index=3&type=section&id=Report%20Signature) The report was officially signed by the Chief Financial Officer of Nutex Health Inc., confirming its submission - The report was signed on behalf of **NUTEX HEALTH INC.** by **Jon C. Bates**, Chief Financial Officer[12](index=12&type=chunk) - Date of signature: **October 20, 2025**[12](index=12&type=chunk)

Core Insights - Nutex Health Inc. reported significant year-over-year growth in patient volume and cash collections for Q3 2025, indicating strong operational momentum and financial performance [1][8]. Financial Performance - Estimated patient volume for Q3 2025 increased to 46,293, representing an 11.1% growth compared to Q3 2024 [2]. - Cash collections for Q3 2025 reached $235,003, reflecting a substantial increase of 258.8% year-over-year [2]. - Year-to-date (YTD) patient volume for 2025 was 140,135, up 14.0% from 2024, while YTD cash collections totaled $546,003, marking a 176.9% increase [2]. Operational Highlights - The growth in patient volume was attributed to strategic facility expansion and increased demand for community-based acute care services [8]. - Enhanced revenue cycle management, improved payer mix, and higher patient acuity contributed to the surge in cash collections [8]. Compliance and Audit Progress - The company is actively working to meet Nasdaq's listing standards and has submitted a plan to regain compliance following a non-compliance notice due to errors in previously issued financial statements [6][7]. - Nutex Health anticipates filing its delinquent Form 10-Q for the period ended June 30, 2025, by December 12, 2025, as part of its compliance efforts [9].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [3][8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10] Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract outsized reimbursements [2][4] - The revenue model of Nutex is described as unstable, with financial statements failing to accurately reflect the company's operations [3] Group 2: Market Reaction - Following the release of a report by Blue Orca Capital, which accused HaloMD of a fraudulent scheme, Nutex shares dropped over 10% [4][5] - After Nutex announced a delay in its Form 10-Q submission, shares plunged 16.39%, closing at $92.91 [7] Group 3: Financial Reporting Issues - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [6] - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classifications [8] Group 4: Investor Impact - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period [10][11] - Plaintiffs argue that the company's public disclosures were materially misleading, leading to significant investor harm when the true financial condition was revealed [11]

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex-h ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) HaloMD, a third-party IDR vendor, was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it h ...

Core Viewpoint - Nutex Health Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its financial practices and internal controls [3][4]. Summary by Sections Allegations - The lawsuit claims that Nutex Health, through its third-party vendor HaloMD, engaged in fraudulent activities to defraud insurance companies, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate weaknesses in its internal financial controls, affecting its accounting for stock-based compensation [3]. - The company reportedly misclassified stock-based compensation obligations as equity instead of liabilities, increasing the risk of delayed financial reporting to the SEC [3]. Class Period and Deadlines - The class period for the lawsuit is from August 8, 2024, to August 14, 2025 [3]. - Shareholders are encouraged to register for the class action by October 21, 2025, to participate in potential recovery [4]. Next Steps for Shareholders - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the lawsuit [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5].

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex collaborated with third-party billing firm HaloMD to submit ineligible insurance claims, misleading shareholders and ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, including the involvement of HaloMD in fraudulent activities to achieve favorable arbitration results [4]. - It is claimed that Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [4]. - The allegations suggest that these misrepresentations inflated Nutex's business and financial prospects, resulting in investor damages when the truth was revealed [4].